Results

RDF/XMLNTriplesTurtleShow queryShare ▶
SubjectPredicateObject
http://purl.uniprot.org/citations/35695793http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/35695793http://www.w3.org/2000/01/rdf-schema#comment"

Objectives

Nab -paclitaxel and gemcitabine (GnP) or FOLFIRINOX (a combination of leucovorin, fluorouracil, irinotecan, and oxaliplatin [FFX]) is currently recognized as the standard first-line regimen for unresectable pancreatic ductal adenocarcinoma (PDAC). Class III β-tubulin (TUBB3) has the potential to predict resistance to taxane in various tumors; therefore, this study aimed to clarify whether TUBB3 is a predictive marker for GnP response.

Methods

We retrospectively reviewed 113 patients with PDAC who received GnP or FFX as first-line chemotherapy and examined immunohistochemically the TUBB3 expression in specimens obtained by endoscopic ultrasound-guided fine-needle aspiration.

Results

High TUBB3 expression was associated with a significantly lower disease control rate ( P = 0.017) and shorter progression-free survival (PFS) ( P = 0.019), and multivariate analysis revealed that TUBB3 expression was an independent variable for PFS in the GnP first-line group ( P = 0.045). In addition, in the FFX first-line group, TUBB3 expression was not correlated with PFS or overall survival (OS). In all 113 patients, TUBB3 expression was not also associated with OS.

Conclusions

Class III β-tubulin might be a predictive factor for the response of GnP, but not a prognostic factor for OS, helping the selection of an optimized first-line chemotherapy regimen for unresectable PDAC."xsd:string
http://purl.uniprot.org/citations/35695793http://purl.org/dc/terms/identifier"doi:10.1097/mpa.0000000000002032"xsd:string
http://purl.uniprot.org/citations/35695793http://purl.uniprot.org/core/author"Fujita Y."xsd:string
http://purl.uniprot.org/citations/35695793http://purl.uniprot.org/core/author"Hayashi K."xsd:string
http://purl.uniprot.org/citations/35695793http://purl.uniprot.org/core/author"Inoue T."xsd:string
http://purl.uniprot.org/citations/35695793http://purl.uniprot.org/core/author"Kato A."xsd:string
http://purl.uniprot.org/citations/35695793http://purl.uniprot.org/core/author"Kato H."xsd:string
http://purl.uniprot.org/citations/35695793http://purl.uniprot.org/core/author"Kataoka H."xsd:string
http://purl.uniprot.org/citations/35695793http://purl.uniprot.org/core/author"Takahashi S."xsd:string
http://purl.uniprot.org/citations/35695793http://purl.uniprot.org/core/author"Yoshida M."xsd:string
http://purl.uniprot.org/citations/35695793http://purl.uniprot.org/core/author"Sano H."xsd:string
http://purl.uniprot.org/citations/35695793http://purl.uniprot.org/core/author"Nishi Y."xsd:string
http://purl.uniprot.org/citations/35695793http://purl.uniprot.org/core/author"Hirano A."xsd:string
http://purl.uniprot.org/citations/35695793http://purl.uniprot.org/core/author"Takada H."xsd:string
http://purl.uniprot.org/citations/35695793http://purl.uniprot.org/core/author"Okumura F."xsd:string
http://purl.uniprot.org/citations/35695793http://purl.uniprot.org/core/author"Natsume M."xsd:string
http://purl.uniprot.org/citations/35695793http://purl.uniprot.org/core/author"Hori Y."xsd:string
http://purl.uniprot.org/citations/35695793http://purl.uniprot.org/core/author"Miyabe K."xsd:string
http://purl.uniprot.org/citations/35695793http://purl.uniprot.org/core/author"Naiki-Ito A."xsd:string
http://purl.uniprot.org/citations/35695793http://purl.uniprot.org/core/author"Naitoh I."xsd:string
http://purl.uniprot.org/citations/35695793http://purl.uniprot.org/core/date"2022"xsd:gYear
http://purl.uniprot.org/citations/35695793http://purl.uniprot.org/core/name"Pancreas"xsd:string
http://purl.uniprot.org/citations/35695793http://purl.uniprot.org/core/pages"372-379"xsd:string
http://purl.uniprot.org/citations/35695793http://purl.uniprot.org/core/title"Class III beta-Tubulin Expression Is of Value in Selecting nab -Paclitaxel and Gemcitabine as First-Line Therapy in Unresectable Pancreatic Cancer."xsd:string
▶